Price$86.61-0.60 (-0.69%)
01:30 PM07:45 PM
News · 26 weeks77-55%
2026-04-192026-10-11
Mix2690d
- Insider13(50%)
- SEC Filings4(15%)
- Other4(15%)
- Analyst3(12%)
- Earnings2(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Edwards Lifesciences Corporation4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- ANALYSTBarclays initiated coverage on Edwards Lifesciences with a new price targetBarclays initiated coverage of Edwards Lifesciences with a rating of Overweight and set a new price target of $110.00
- PREdwards Lifesciences to Host Earnings Conference Call on November 4, 2026Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and heal
- PREdwards Lifesciences to Host Investor Event in Conjunction With TCTEdwards Lifesciences (NYSE:EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class
- PREdwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric PatientsEdwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy, with the ability to be expanded as a child grows. Valve expansion is performed through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. "Children with congenital pulmona
- INSIDERSVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- INSIDERCVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- INSIDERCVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- INSIDERCVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- PREdwards Lifesciences Comments on TAVR National Coverage DecisionEdwards Lifesciences (NYSE:EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):"Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, progressive disease, and delays in evaluation, diagnosis and treatment increase the risk of irreversible heart damage and hospitalization, leading to poorer outcomes and higher healthcare costs, as well as an increased risk of death. The mod
- PREdwards Lifesciences to Present at the Deutsche Bank Healthcare SummitEdwards Lifesciences Corporation (NYSE:EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day.About Edwards LifesciencesEdwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p
- INSIDERSVP, Corporate Controller Dahl Andrew M. sold $49,534 worth of shares (544 units at $91.06), decreasing direct ownership by 4% to 14,868 units (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- INSIDERCVP, EMEACLA Bruls Annette sold $237,907 worth of shares (2,644 units at $89.98), decreasing direct ownership by 13% to 17,984 units (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- SECEdwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update8-K - Edwards Lifesciences Corp (0001099800) (Filer)
- INSIDERCVP, TMTT, Surgical & IHFM Chopra Daveen exercised 31,800 shares at a strike of $72.68 and sold $2,894,440 worth of shares (31,800 units at $91.02) (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- INSIDERCVP, JAPAC Markowitz Wayne sold $113,417 worth of shares (1,240 units at $91.47), decreasing direct ownership by 6% to 20,294 units (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- INSIDERCVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- SECSEC Form S-8 filed by Edwards Lifesciences CorporationS-8 - Edwards Lifesciences Corp (0001099800) (Filer)
- SECSEC Form 10-Q filed by Edwards Lifesciences Corporation10-Q - Edwards Lifesciences Corp (0001099800) (Filer)
- INSIDERCVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- INSIDERCVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- ANALYSTUBS initiated coverage on Edwards Lifesciences with a new price targetUBS initiated coverage of Edwards Lifesciences with a rating of Buy and set a new price target of $110.00
- INSIDERCEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)4 - Edwards Lifesciences Corp (0001099800) (Issuer)
- ANALYSTEdwards Lifesciences upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Edwards Lifesciences from Market Perform to Outperform and set a new price target of $101.00
- SECEdwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edwards Lifesciences Corp (0001099800) (Filer)
EW FAQ
6 questionsWhat does Edwards Lifesciences Corporation do?
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty...Where does EW stock trade?
Edwards Lifesciences Corporation (EW) is listed on NYSE.What sector and industry is EW in?
Edwards Lifesciences Corporation operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about EW?
Edwards Lifesciences Corporation has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-10-07.What companies are similar to EW?
Notable peers in the same industry include MDT (Medtronic plc.), BDX (Becton Dickinson and Company), ICUI (ICU Medical Inc.). Compare EW side-by-side with any of them on Quantisnow.How can I track EW on Quantisnow?
Quantisnow aggregates Edwards Lifesciences Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EW to receive live email and push alerts on every new disclosure.